Also trades as: 94E.F (FSX) · $vol 0M
ZURA NASDAQ
Zura Bio Limited
1W: +1.7%
1M: -27.5%
3M: -23.3%
YTD: -25.9%
1Y: +1.7%
3Y: -39.1%
$4.11
-0.03 (-0.72%)
Weekly Expected Move ±7.5%
$3
$4
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
34 relationships34
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2021-08-11
Earliest Filing
2026-01-02
Latest Filing
investor: 15
target: 9
partner: 8
acquirer: 1
licensee: 1
Counterparties (Filed by ZURA)
34 relationshipsCompanies named in ZURA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Athanor Capital | — | acquirer | Acquired rights previously held by Stone Peach and entered into a new agreement with Zura Bio Limited. | 2026-01-02 | View |
| Stone Peach Properties LLC | — | partner | Previous partner whose agreements with Zura Bio Limited were terminated and released. | 2026-01-02 | View |
| BAFFX17 | — | partner | Previous partner whose agreements with Zura Bio Limited were terminated and released. | 2026-01-02 | View |
| Z33 Bio Inc. | — | partner | Subsidiary involved in previous letter agreements with Stone Peach that were terminated. | 2026-01-02 | View |
| ZB17 LLC | — | partner | Subsidiary involved in previous letter agreements with Stone Peach that were terminated. | 2026-01-02 | View |
| Eli Lilly and Company | LLY | licensee | Holds a license agreement with ZB17 LLC relevant to royalty payments under the new Athanor Agreement. | 2026-01-02 | View |
| Venrock Healthcare Capital Partners | — | investor | Shareholders surrendering shares and receiving pre-funded warrants | 2025-04-17 | View |
| AI Biotechnology | — | investor | Shareholder surrendering shares and receiving pre-funded warrants | 2025-04-17 | View |
| Eli Lilly and Company | LLY | partner | Entered into a License, Development and Commercialization Agreement for ZB-106 and an Equity Grant Agreement for 1,000,0 | 2023-05-03 | View |
| JATT Ventures, L.P. | — | investor | Sponsor entity that entered into a support agreement with JATT and Zura. | 2023-03-24 | View |
| Ewon Comfortech Co., Ltd. | — | investor | Institutional accredited investor that purchased JATT Class A Ordinary Shares in the PIPE Financing. | 2023-03-24 | View |
| Hana Immunotherapeutics LLC | — | investor | Entity in which Ewon Comfortech Co., Ltd. holds an equity interest. | 2023-03-24 | View |
| Athanor Master Fund, LP | — | investor | Unaffiliated institutional investor that purchased JATT Class A Ordinary Shares under the Forward Purchase Agreement. | 2023-03-24 | View |
| Athanor International Master Fund, LP | — | investor | Unaffiliated institutional investor that purchased JATT Class A Ordinary Shares under the Forward Purchase Agreement. | 2023-03-24 | View |
| Eli Lilly and Company | LLY | partner | Counterparty to the JATT Equity Grant Agreement and Lilly Lock-Up Agreement. | 2023-03-24 | View |
| Athanor Master Fund, LP | — | investor | Purchaser in the Forward Purchase Agreement. | 2023-03-10 | View |
| Athanor International Master Fund, LP | — | investor | Purchaser in the Forward Purchase Agreement. | 2023-03-10 | View |
| Zura Bio Limited | ZURA | target | Target company in the proposed business combination with JATT Acquisition Corp. | 2023-03-10 | View |
| Hana Immunotherapeutics LLC | — | investor | Entity expected to own Class A Shares of the post-combination company. | 2023-03-10 | View |
| Willow Gate LLC | — | investor | Entity expected to own Class A Shares of the post-combination company. | 2023-03-10 | View |
| Stone Peach Properties LLC | — | investor | Entity expected to own Class A Shares of the post-combination company. | 2023-03-10 | View |
| Zura Bio Limited | ZURA | target | Target company in the proposed business combination with JATT Acquisition Corp. | 2023-01-19 | View |
| Zura Bio Holdings Ltd | ZURA | target | Target company in the proposed business combination with JATT Acquisition Corp. | 2023-01-19 | View |
| Eli Lilly and Company | LLY | partner | Pharmaceutical company granting IP license to Z33 and receiving equity from JATT | 2022-12-12 | View |
| Zura Bio Holdings Ltd | ZURA | target | Target company entering business combination with JATT Acquisition Corp | 2022-12-12 | View |
| Zura Bio Limited | ZURA | target | Target company (Zura) entering business combination with JATT Acquisition Corp | 2022-12-12 | View |
| Z33 Bio Inc. | — | partner | Entity controlled by Zura entering license agreement with Eli Lilly | 2022-12-12 | View |
| Zura Bio Holdings Ltd | ZURA | target | Target company in the proposed business combination with JATT Acquisition Corp. | 2022-11-15 | View |
| Zura Bio Limited | ZURA | target | Target company in the proposed business combination with JATT Acquisition Corp. | 2022-11-15 | View |
| JATT Ventures, L.P. | — | investor | Sponsor entity entering a support agreement to vote in favor of the Business Combination. | 2022-06-17 | View |
| Zura Bio Limited | ZURA | target | Target company incorporated under the laws of England and Wales entering the Business Combination Agreement. | 2022-06-17 | View |
| Zura Bio Holdings Ltd | ZURA | target | Holdco established to become a party to the Business Combination Agreement prior to Closing. | 2022-06-17 | View |
| Athanor Master Fund LP | — | investor | Purchaser of 7,500,000 forward purchase shares in a forward purchase agreement | 2021-08-11 | View |
| Athanor International Master Fund, LP | — | investor | Purchaser of 7,500,000 forward purchase shares in a forward purchase agreement | 2021-08-11 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-17 | Regulation FD; Exhibits | View | |
| 2026-08-11 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-07-01 | Regulation FD; Exhibits | View | |
| 2026-06-18 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-22 | Officer/Director Change | View | |
| 2026-05-07 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-04-23 | Officer/Director Change; Exhibits | View | |
| 2026-03-10 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-03-05 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-02-26 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Other Event | Agreement | View |
| 2026-02-26 | Financial Statements and Exhibits | View | |
| 2026-02-23 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2026-02-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-26 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2026-01-12 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2026-01-02 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Unregistered | Agreement | View |
| 2025-12-17 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-10 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-09-30 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR